LOWELL, Mass.–(BUSINESS WIRE)–RevBio, Inc., announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute on Aging, part of the National Institutes of Health. This funding will allow the company to pursue the treatment of vertebral compression fractures with its patented bone adhesive technology known as Tetranite®. Because the osteoconductive bone adhesive is injectable, the material may be delivered in a minimally invasive procedure.
“The adhesive and structural features of this biomaterial combined with the fact that it is osteoconductive and ultimately replaced by bone make it an excellent candidate for an improved vertebroplasty procedure,” said Dr. Kevin T. Foley M.D., Professor of Neurosurgery, Orthopedic Surgery, and Biomedical Engineering at the University of Tennessee Health Science Center, Chairman of the Semmes Murphey Spinal Care Clinic, and a recognized pioneer in the development of minimally invasive spine surgery. “This regenerative, adhesive, and cohesive material delivered percutaneously could significantly improve the way these fractures are treated.”